D-0119-2017 Class III Terminated
FDA drug recall D-0119-2017 was initiated by Par Pharmaceutical, Inc. on Sep 27, 2016 and is designated Class III. Reason for recall: Subpotent Drug; Ethinyl Estradiol The recall status is terminated (terminated Nov 5, 2026). Affected quantity: 221,017 tablets.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 9, 2016
- Initiation Date
- Sep 27, 2016
- Termination Date
- Nov 5, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 221,017 tablets
Product description
Gildess 1.5/30 (norethindrone acetate, 1.5 mg and ethinyl estradiol tablets, 0.03 mg, USP), 21 count, (a) 3 blisters (NDC 0603-7606-48) and (b) 6 blisters (NDC 0603-7606-15), Rx only, Manufactured in Canada By: Patheon, Inc., Ontario, Canada L5N 7K9, Manufactured for QUALITEST PHARMACEUTICALS, USA, Huntsville, AL 35811
Reason for recall
Subpotent Drug; Ethinyl Estradiol
Distribution pattern
Nationwide and Puerto Rico
Code information
Lot Numbers (a) 4169949, 4297235, 4359298, 4501268, 4614353 (b) 4101064, 4196576, 4228443, 4265206, 4265207, 4267685, 4365281, 4365284, 4365289, 4501276, 4563354, 4563355, 4614354, 4731574, 4731575, 4793332, 4798708, 4798709
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0119-2017
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026